Laura Calatayud

Laura Calatayud

Auto-generated profile, based on publicly available information

Laura Calatayud

Microbiology Department, Hospital Universitari de Bellvitge - Bellvitge Biomedical Research Institute (IDIBELL) - University of Barcelona (UB), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ACAránzazu Caballero‐Marcos
Aránzazu Caballero‐Marcos
MSMagdalena Salcedo
Magdalena Salcedo
RARoberto Alonso‐Fernández
Roberto Alonso‐Fernández
Manuel Rodríguez-PerálvarezManuel Rodríguez-Perálvarez
Manuel Rodríguez-Perálvarez
MSMARIA Olmedo Samperio
MARIA Olmedo Samperio
T(The Spanish Society Of Liver Transplantation (Seth)
The Spanish Society Of Liver Transplantation (Seth)
The protective capacity and duration of humoral immunity after SARS‐CoV‐2 infection is not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti‐nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID‐19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well‐known prognostic impact in COVID‐19. Paired case‐control serological data was also available in 62 liver transplant patients and 62 controls at month 3 after COVID‐19. Liver transplant recipients showed a lower incidence of anti‐nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p<0.001) and at 6 months (63.4% vs. 90.1%, p<0.001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p=0.001) and 6 months (p<0.001) after COVID‐19. In transplant patients, female gender (OR=13.49, 95%CI 2.17‐83.8), a longer interval since transplantation (OR=1.19, 95%CI 1.03‐1.36), and therapy with renin–angiotensin–aldosterone system inhibitors (OR=7.11, 95%CI 1.47‐34.50) were independently associated with persistence of antibodies beyond 6 months after COVID‐19. Therefore, as compared with immunocompetent patients, liver transplant recipients show a lower prevalence of anti‐SARS‐CoV‐2 antibodies and more pronounced antibody levels decline.

1 October 2014 in Microbial Drug Resistance
Verified
Journal Article
Open access
CPCarmen Puig
Carmen Puig
SMSara Marti
Sara Marti
AFAna Fleites
Ana Fleites
RTRafael Trabazo
Rafael Trabazo
LCLaura Calatayud
Laura Calatayud
ACArdanuy Carmen
Ardanuy Carmen
Haemophilus influenzae colonizes the upper respiratory tract and can spread causing otitis and sinusitis. This work aimed to study the oropharyngeal carriage rate in healthy <5-year-old children attending day care centers in Oviedo, Spain in two consecutive years (January to March 2004–2005). The carriage rate was 42% (400/960) and highly variable among centers (range, 12% to 83%). Isolates were mainly identified as nontypeable H. influenzae (NTHi, 99%). Epidemiologically, 127 different genotypes were identified by PFGE with a minimum of two genotypes per center. One hundred fourteen children (12%) were included in both studies and none of them harbored the same strain over a period of time. The isolates only showed resistance to cotrimoxazol and ampicillin, presenting a shift in the level of ampicillin reduced susceptibility, showing a predominance of PBP3 mutations in 2004 and a predominance of β-lactamase production in 2005. This study proved the great genetic variability of NTHi isolates that present similar genotypic patterns in both years with no long-term carriage of the same strain.

1 February 2017 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
SGSilvia Gómez-Zorrilla
Silvia Gómez-Zorrilla
LCLaura Calatayud
Laura Calatayud
Carlos JuanCarlos Juan
Carlos Juan
GCGabriel Cabot
Gabriel Cabot
FTFe Tubau
Fe Tubau
CPCarmen Peña
Carmen Peña

15 October 2015 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
SMSara Marti
Sara Marti
CPCarmen Puig
Carmen Puig
ACAdela G. De La Campa
Adela G. De La Campa
JVJosé Manuel Tirado Vélez
José Manuel Tirado Vélez
FTFe Tubau
Fe Tubau
ACArdanuy Carmen
Ardanuy Carmen
The objectives of this study were to establish the frequency of Haemophilus haemolyticus in clinical samples, to determine the antimicrobial resistance rate and to identify the mechanisms of resistance to β-lactams and quinolones. An updated database was used to differentiate between MALDI-TOF MS results for Haemophilus influenzae and H. haemolyticus. Antimicrobial susceptibility was studied by microdilution, following EUCAST criteria. The β-lactamase types were identified by PCR analysis of isolates that tested positive for nitrocefin hydrolysis. Mutations in the ftsI gene were identified in isolates with ampicillin MICs ≥0.25 mg/L. Mutations in the quinolone resistance-determining region (QRDR) were identified in isolates with ciprofloxacin MICs ≥0.5 mg/L. Overall, we identified 69 H. haemolyticus isolates from 1706 clinical isolates of Haemophilus spp. from respiratory, genital, invasive, and other infection sources. The frequency of H. haemolyticus was low in respiratory samples compared with that of H. influenzae, but in genital-related samples, the frequency was similar to that of H. influenzae. We found low antimicrobial resistance rates among H. haemolyticus isolates, with 8.7% for ampicillin, 8.7% for co-trimoxazole, 7.2% for tetracycline and 4.3% for ciprofloxacin. Mutations in the ftsI gene classified the isolates into four groups, including the newly described Group Hhae IV, which presents mutations in the ftsI gene not identified in H. influenzae and H. haemolyticus type strains. Three ciprofloxacin-resistant H. haemolyticus isolates with mutations affecting GyrA and ParC were identified. The frequency of H. haemolyticus was low, especially in respiratory samples, where H. influenzae is the main pathogen of this genus. Although antimicrobial resistance rates were low, three ciprofloxacin-resistant H. haemolyticus clinical isolates have been identified for the first time.

5 August 2025 in Journal of Infection
Verified
Journal Article
Open access
AGAlejandra González-Sánchez
Alejandra González-Sánchez
CACristina Andrés
Cristina Andrés
IPIgnasi Prats-Méndez
Ignasi Prats-Méndez
MPMaria Piñana
Maria Piñana
ECErmengol Coma
Ermengol Coma
AAAndrés Antón
Andrés Antón
To evaluate the effect of the selective pressure exerted by nirsevimab on human respiratory syncytial virus (HRSV) in Catalonia (2023-2024) by analysing viral mutations, diversity, and evolutionary dynamics, based on viruses characterised from non-immunised and previously immunised patients. Respiratory samples were collected through the SIVIC sentinel network and three hospitals in Catalonia. HRSV-positive samples underwent whole-genome sequencing (WGS), or F gene sequencing when WGS was not feasible. Viral diversity, phylogenetics, and selection pressure were assessed. A total of 251 WGS (HRSV-A: 165; HRSV-B: 86) and 27 F gene sequences (HRSV-A: 13; HRSV-B: 14) were obtained for the non-immunised group. For immunised cases, 79 WGS (HRSV-A: 67; HRSV-B: 12) and 12 F sequences (HRSV-A: 10; HRSV-B: 2) were analysed. Lineage distribution remained similar between groups. Nucleotide diversity was similar for HRSV-A groups, though reduced in immunised HRSV-B. Selection pressure analyses suggested a shift toward neutral evolution in immunised samples. Mutations N63S, K65R, I206T, and K209E (HRSV-A) and K68E, R209Q, and S211N (HRSV-B) were detected in nirsevimab epitope, with K209E and K68E absent in non-immunised samples. Nirsevimab immunisation may influence HRSV evolution, particularly in HRSV-B. Continued genomic surveillance is crucial for early mAb-resistant mutants detection.

12 April 2022 in Trials
Verified
Journal Article
Open access
PDF file
PMPierre Malchair
Pierre Malchair
Aurema OteroAurema Otero
Aurema Otero
JGJordi Giol
Jordi Giol
XSXavier Solanich
Xavier Solanich
TCThiago Carnaval
Thiago Carnaval
AZAlvaro Zarauza
Alvaro Zarauza
Background: COVID-19 has quickly become a global pandemic with a substantial number of deaths and is a considerable burden for healthcare systems worldwide. Although most cases are paucisymptomatic and limited to the viral infection-related symptoms, some patients evolve to a second phase, with an impaired inflammatory response (cytokine storm) that may lead to acute respiratory distress syndrome and death. This is thought to be caused by increased bradykinin synthesis. Methods: ICAT-COVID is a multicenter, randomized, open-label, proof-of-concept phase II clinical trial assessing the clinical efficacy and safety of adding icatibant to the standard of care in patients hospitalized with COVID-19 without invasive mechanical ventilation. Patients hospitalized with a confirmed COVID-19 pneumonia diagnosis (RT-PCR or antigen test ≤ 10 days prior to randomization, and radiographic evidence of pulmonary infiltrates), rated “4” or “5” on the WHO’s clinical status scale, are eligible. Patients will be randomized on a 1:1 ratio to either standard of care-plus-icatibant (experimental group) or to standard of care alone (control group). The experimental group will receive 30 mg of icatibant subcutaneously 3 times a day for 3 days (for a total of 9 doses). The expected sample size is 120 patients (60 per group) from 2 sites in Spain. Primary outcomes are the efficacy and safety of Icatibant. The main efficacy outcome is the number of patients reaching grades “2” or “1” on the WHO scale within 10 days of starting treatment. Secondary outcomes include “long-term efficacy”: number of patients discharged who do not present COVID-19-related relapse or comorbidity up until 28 days after discharge, and mortality. Discussion: Icatibant, a bradykinin type 2 receptor antagonist with proven effectiveness and safety against hereditary angioedema attacks, may be beneficial for COVID-19 patients by inhibiting bradykinin’s action on endothelial cells and by inhibiting the SARS-CoV-2 M protease. Our working hypothesis is that treatment with standard of care-plus-icatibant is effective and safe to treat patients infected with SARS-CoV-2 admitted to hospital for pneumonia without invasive mechanical ventilation. Trial registration: EudraCT 2020-002166-13. ClinicalTrials.gov NCT04978051